TRU - Truscreen

[Balance]

......Truscreen doing very very well and I personally haven't lost a cent here. You need to research the company and it's product NOT the shareholders before making such a ridiculous judgement call. Please correct me if I'm wrong but I'm pretty sure the Sorrensons have had zilch to do with the development of the Truscreen wand and it's technology??

Your first posting on this thread GR8DAY (31 May 2015) is below - sp then was 18c and now it is 12c, and you say you have not lost a cent?

Give you a chance to explain before I call you for what I believe you are.

.....golly gosh, this could be big.....could be huge. Why hasnt the market reacted accordingly? Dont know anything about them but surely this must be very promising?? Anyone care to clarify/comment? whats the history of this co. re losses/ cash burn etc??



Announcement
GENERAL: TRU: TRUSCREEN SELECTED FOR MAJOR CHINESE SCREENING PROGRAMME 08:31a.m.
TRU
31/05/2016 08:30
GENERAL
PRICE SENSITIVE
REL: 0830 HRS TruScreen Limited

GENERAL: TRU: TRUSCREEN SELECTED FOR MAJOR CHINESE SCREENING PROGRAMME

Company Announcement
31 May 2016

TRUSCREEN SELECTED FOR MAJOR CHINESE SCREENING PROGRAMME

o TruScreen to announce FY16 results on 13 June 2016

o NZX approval received to remain on NZAX platform for a further 12 months

Cancer technology company TruScreen Limited (NZAX: TRU) advises that its
technology has been selected for use in a major cervical cancer screening
programme in North China.

The public screening programme is expected to screen 160,000 women over the
next 18 months and is being funded by the Harbin Division of the All China
Federation of Trade Unions ("ACFTU"). The programme is being conducted under
the control of the Provincial Cancer Hospital of Heilongjiang, located in
Harbin City, and involves a number of other leading hospitals in the
Province. TruScreen has satisfactorily completed all medical device
accreditation and verification requirements and completed training of all
medical teams involved.

CEO of TruScreen, Mr Martin Dillon, said: "Providing our technology for use
in fully funded public screening campaigns for cervical cancer in the
enormous Chinese market is an important part of our strategy. ACFTU is the
largest trade union in the world with over 280 million members, and we are
delighted to be affiliated with this programme. We hope to leverage off
this association and extend the use of the TruScreen technology to similar
programmes in other provinces throughout China".

The TruScreen system was selected due to a combination of its real time
nature and its high ability to identify disease, alongside its portability
and independence from laboratory infrastructure. This is different to other
available screening methods and enables the speedy implementation of a large
population based screening program.

TruScreen is the only real time device in the world that is CE certified for
the stand-alone primary screening of cervical cancer. It successfully
combines the use of both optical and electrical tissue differentiation to
create a clinically acceptable level of performance as a primary screening
tool.

TruScreen to Announce FY16 Results on 13 June 2016; Approval to remain on
NZAX Platform

TruScreen advises that it expects to announce its full year results for the
year ended 31 March 2016, by 14 June 2016. In addition, the company has
confirmed that it has received notice that it will not need to migrate it's
listing to the NXT Market platform operated by NZX Limited during the next 12
months.

ENDS